Dec 14, 2021   SOURCE: BusinessWire

H.I.G. Capital Completes Strategic Investment in Rising Pharmaceuticals

H.I.G. Capital ("H.I.G."), a leading global alternative investment firm with over $45 billion of equity capital under management, is pleased to announce that one of its affiliates has made a strategic equity investment into Rising Pharma Holdings and Casper Pharma (collectively, “Rising Pharmaceuticals” or the “Company”), a leading provider of generic and specialty pharmaceuticals in the United States.

Rising Pharmaceuticals develops and markets generic and specialty branded pharmaceutical products across various therapeutic categories. The Company employs an asset-light model with a fully outsourced third party network, which provides robust capabilities across multiple dosage forms. With a diversified portfolio of over 125 products and the ability to quickly commercialize complex molecules, Rising Pharmaceuticals is strategically positioned in the U.S. pharmaceuticals market. H.I.G. has partnered with Vimal Kavuru, CEO of Rising Pharmaceuticals, to continue the Company’s strong track record of growth and to support new initiatives, such as M&A and new product launches.

"We are excited to partner with Vimal Kavuru and Rising Pharmaceutical’s exceptional management team," said Mike Gallagher, Managing Director at H.I.G. "As partners, we look forward to supporting Vimal and his team to further build upon Rising Pharmaceutical’s tremendous success. We see a major opportunity in the broader U.S. generic pharmaceutical industry, and the Company’s track record of identifying, developing and launching complex pharmaceutical products should create an exciting next chapter for Rising Pharmaceuticals.”

“We are enthusiastic to enter into this new chapter of growth with H.I.G.,” said Vimal Kavuru, Founder and CEO of Rising Pharmaceuticals. "We have built an outstanding business model, as evidenced by our strong growth, stellar customer service levels and tremendous support from our customers and partners. We look forward to accelerating Rising Pharmaceutical’s growth trajectory with H.I.G., which brings significant experience and resources in the pharmaceutical sector, while continuing to support our customers and suppliers with top-notch service.”

H.I.G.’s investment in Rising Pharmaceuticals represents its latest transaction in the pharma services sector. Other active H.I.G. pharma services investments include Aspire Pharma, BioVectra, Leiters and Taconic BioSciences.

About Rising Pharmaceuticals

Rising Pharmaceuticals and its affiliates is a provider of generic and specialty-branded pharmaceuticals. Rising focuses on the development, regulatory, and commercial aspects of the product life cycle while outsourcing manufacturing to its network of 23+ strategic CMO and CDO partners. The Company is based in New Brunswick, New Jersey. For more information about the Company, please visit www.risingpharma.com.

About H.I.G. Capital

H.I.G. is a leading global alternative assets investment firm with over $45 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, Atlanta and Stamford in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused / value-added approach:

1.

H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming businesses.

 

 

2.

H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.

 

 

3.

H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.

 

 

4.

H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.

Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of $30 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.

* Based on total capital commitments managed by H.I.G. Capital and affiliates.